Avita Medical, Inc.

Sep 2, 2026

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

AVITA Medical, a leader in acute wound care, will participate in two significant investor conferences in September 2026. The Lake Street Best Ideas Growth Conference and the Morgan Stanley Healthcare Conference will feature senior management, including CEO Cary Vance. A live audio webcast of the Morgan Stanley fireside chat will be available for 90 days post-event.

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

AVITA Medical announced positive results from its PermeaDerm-I clinical study, showing that PermeaDerm, a biosynthetic wound matrix, offers a 70% cost advantage over cadaveric allograft while achieving comparable clinical outcomes. The study demonstrated a significant reduction in preparation time and high patient satisfaction. AVITA will host a webinar to discuss the findings further.

Aug 9, 2026

AVITA Medical to Host Investor Webinar Briefing

AVITA Medical is set to host an investor webinar on August 12, 2026, featuring insights from CEO Cary Vance and CFO David O'Toole. The session will discuss the company's second-quarter financial results and include a Q&A segment. Interested participants can register via a provided Zoom link.

Aug 7, 2026

▲ +63.6%on this news

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

AVITA Medical, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11-13, 2026. CEO Cary Vance is scheduled to speak on August 12 at 8:00 a.m. ET. Investors can request one-on-one meetings through Canaccord Genuity representatives. The company focuses on advanced wound care solutions, including the FDA-approved RECELL technology.

Aug 6, 2026

▲ +63.6%on this newsshared move

AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven

AVITA Medical reported strong second quarter results with a record revenue of $21.7 million, reflecting an 18% increase year-over-year. The company raised its full-year revenue guidance to between $86 million and $89 million and anticipates reaching cash flow breakeven in the fourth quarter of 2026. Key products such as RECELL, Cohealyx, and PermeaDerm contributed significantly to this growth.

Jul 14, 2026

▲ +17.7%on this news· ran to +28% by day 3

AVITA Medical to Announce Second Quarter 2026 Financial Results

AVITA Medical, Inc. will announce its second quarter 2026 financial results on August 6, 2026. A conference call and webcast are scheduled for the same day to discuss the results and recent business highlights. The company continues to promote its RECELL technology, which is approved for various wound care applications.

Jun 18, 2026

AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting

AVITA Medical presented the first U.K. clinical experience with RECELL GO at the British Burn Association Annual Meeting. The case series involved 17 patients treated at Stoke Mandeville Hospital, showcasing successful outcomes in burn and reconstructive surgeries. The findings highlight the system's ability to standardize skin cell preparation and enhance operating room efficiency.

May 14, 2026

AVITA Medical Reports First Quarter 2026 Financial Results

AVITA Medical reported its financial results for the first quarter of 2026, revealing a total revenue of approximately $19.3 million, reflecting a 4% increase from the previous year. The company announced the appointment of Cary Vance as CEO, indicating a strategic leadership change. Despite achieving a gross profit margin of 81.7%, AVITA also reported a net loss of $10.6 million and cash use of $9.9 million for the quarter. Furthermore, AVITA reaffirmed its full-year guidance, expecting revenue growth between 12% to 19% compared to 2025.

Apr 30, 2026

AVITA Medical Names Cary Vance as Chief Executive Officer -Board appoints Cary Vance as President and Chief Executive Officer

AVITA Medical has appointed Cary Vance as its permanent President and Chief Executive Officer effective immediately, following a successful interim tenure. The Board made this decision after a thorough search process, highlighting Vance's decisive leadership and deep industry experience. Alongside this, Jan Stern Reed has been appointed as Chair of the Board, further emphasizing the company's strategic commitment to growth. Under Vance's leadership, AVITA aims to scale adoption of its products, focusing on improved patient outcomes.

Apr 29, 2026

RCELFDA Updates

AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

AVITA Medical has announced that its RECELL GO system has received regulatory clearances from Australia's TGA and New Zealand's Medsafe. This certification allows for the commercialization of RECELL GO in both countries, promoting standardized and automated skin preparation for burn and trauma treatment. The initial commercial launch is expected to take place shortly through their distribution partner, Revolution Surgical. The innovation promises to enhance clinical efficiency and improve access to treatment for patients in these regions.

AVITA Medical to Announce First Quarter 2026 Financial Results

AVITA Medical, a leader in therapeutic acute wound care, will announce its first quarter 2026 financial results on May 14, 2026. The company plans to host a conference call and webcast at 1:30 p.m. Pacific Time to discuss these results and highlight recent business developments. AVITA Medical specializes in wound healing solutions, particularly through its RECELL technology, which is FDA-approved for the treatment of thermal burn and trauma wounds.

AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association

AVITA Medical has announced that its founder, Professor Fiona Wood, received the Lifetime Achievement Award from the American Burn Association. This prestigious recognition honors her groundbreaking work in burn care, which includes the development of the RECELL® Spray-On Skin™ technology. Wood's innovative methods have not only advanced treatment practices but also inspired ongoing research and education in the field. Her influence spans over three decades, establishing a legacy that continues to guide current medical practices in burn care.

▲ +14.1%on this newsshared move

Apr 14, 2026

RCELPhases

AVITA Medical Announces Positive Interim Results from Cohealyx Study Demonstrating Accelerated Time to Skin Grafting

AVITA Medical has announced positive interim results from its Cohealyx-I study, highlighting a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The study demonstrated a mean time of 13.6 days compared to a 33.2 days benchmark, with some patients being grafted as early as 5 days. The statistical superiority of the results supports the product's potential for wider clinical adoption. The full dataset is expected in 2026, and management will hold a webinar to discuss the findings shortly.

Apr 13, 2026

AVITA Medical, Inc. Investigated by the Portnoy Law Firm

AVITA Medical, Inc. is currently under investigation by the Portnoy Law Firm for possible securities fraud, which may lead to a class action lawsuit on behalf of investors. The Company experienced a significant stock price decline of 21% following the release of disappointing second quarter financial results, which revealed issues related to unpaid provider claims impacting product demand. This situation has created uncertainty in the market and affected the utilization of AVITA's RECELL treatment. Investors are encouraged to discuss their legal options with the law firm.

Apr 8, 2026

▲ +5.9%on this news· ran to +27% by day 3shared move

AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness

AVITA Medical, Inc. has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), valued at up to $25.5 million, to bolster U.S. burn emergency preparedness. This contract ensures nationwide access to RECELL products during mass casualty incidents and demonstrates AVITA's commitment to supporting national health resilience. The agreement outlines maintenance for an inventory of RECELL for deployment and requires AVITA to provide logistical support and immediate readiness in emergencies.

Apr 7, 2026

AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data

AVITA Medical showcased its acute burn and wound care portfolio at the 2026 American Burn Association Annual Meeting, presenting new clinical study data on Cohealyx along with data on RECELL and PermeaDerm. The interim analysis of the Cohealyx multi-center study highlights potential improvements in patient outcomes and reduced hospital length of stay. The company also introduced a new booth experience emphasizing faster recovery for patients. Overall, the event featured numerous presentations reinforcing AVITA's commitment to optimizing wound healing.

Feb 23, 2026

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

AVITA Medical, Inc. is set to participate in the TD Cowen 46th Annual Health Care Conference, taking place in Boston, MA on March 4, 2026. Interim CEO Cary Vance and CFO David O’Toole will lead a presentation and fireside chat during the event. AVITA Medical is known for its RECELL technology, which transforms patient recovery in acute wound care. This event highlights the company’s commitment to advancing its therapeutic solutions.

Feb 12, 2026